Genprex is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.
The passion for gene therapy and the new era of cell and gene-based medicine has made its way to the mainstream for treatment of serious diseases.
The gene therapy market is experiencing tremendous excitement, and these acquisitions strengthen the position that gene therapy is now a significant and key treatment option for patients with serious diseases or cancer.
The IASLC 2019 Targeted Therapies of Lung Cancer Meeting left attendees feeling energized about the incredible work being done to improve patient outcomes for those with lung cancer.
Roche’s acquisition of Spark Therapeutics confirms that gene therapy has finally made its debut as a treatment option for serious diseases.